BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 11882390)

  • 1. In addition to the SH3 binding region, multiple regions within the N-terminal noncatalytic portion of the cAMP-specific phosphodiesterase, PDE4A5, contribute to its intracellular targeting.
    Beard MB; Huston E; Campbell L; Gall I; McPhee I; Yarwood S; Scotland G; Houslay MD
    Cell Signal; 2002 May; 14(5):453-65. PubMed ID: 11882390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cAMP-specific phosphodiesterase PDE4A5 is cleaved downstream of its SH3 interaction domain by caspase-3. Consequences for altered intracellular distribution.
    Huston E; Beard M; McCallum F; Pyne NJ; Vandenabeele P; Scotland G; Houslay MD
    J Biol Chem; 2000 Sep; 275(36):28063-74. PubMed ID: 10829034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The SH3 domain of Src tyrosyl protein kinase interacts with the N-terminal splice region of the PDE4A cAMP-specific phosphodiesterase RPDE-6 (RNPDE4A5).
    O'Connell JC; McCallum JF; McPhee I; Wakefield J; Houslay ES; Wishart W; Bolger G; Frame M; Houslay MD
    Biochem J; 1996 Aug; 318 ( Pt 1)(Pt 1):255-61. PubMed ID: 8761480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2.
    Bolger GB; Peden AH; Steele MR; MacKenzie C; McEwan DG; Wallace DA; Huston E; Baillie GS; Houslay MD
    J Biol Chem; 2003 Aug; 278(35):33351-63. PubMed ID: 12810716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association with the SRC family tyrosyl kinase LYN triggers a conformational change in the catalytic region of human cAMP-specific phosphodiesterase HSPDE4A4B. Consequences for rolipram inhibition.
    McPhee I; Yarwood SJ; Scotland G; Huston E; Beard MB; Ross AH; Houslay ES; Houslay MD
    J Biol Chem; 1999 Apr; 274(17):11796-810. PubMed ID: 10206997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The unique N-terminal domain of the cAMP phosphodiesterase PDE4D4 allows for interaction with specific SH3 domains.
    Beard MB; O'Connell JC; Bolger GB; Houslay MD
    FEBS Lett; 1999 Oct; 460(1):173-7. PubMed ID: 10571082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. UCR1 and UCR2 domains unique to the cAMP-specific phosphodiesterase family form a discrete module via electrostatic interactions.
    Beard MB; Olsen AE; Jones RE; Erdogan S; Houslay MD; Bolger GB
    J Biol Chem; 2000 Apr; 275(14):10349-58. PubMed ID: 10744723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression, intracellular distribution and basis for lack of catalytic activity of the PDE4A7 isoform encoded by the human PDE4A cAMP-specific phosphodiesterase gene.
    Johnston LA; Erdogan S; Cheung YF; Sullivan M; Barber R; Lynch MJ; Baillie GS; Van Heeke G; Adams DR; Huston E; Houslay MD
    Biochem J; 2004 Jun; 380(Pt 2):371-84. PubMed ID: 15025561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and characterization of PDE4A11, a novel, widely expressed long isoform encoded by the human PDE4A cAMP phosphodiesterase gene.
    Wallace DA; Johnston LA; Huston E; MacMaster D; Houslay TM; Cheung YF; Campbell L; Millen JE; Smith RA; Gall I; Knowles RG; Sullivan M; Houslay MD
    Mol Pharmacol; 2005 Jun; 67(6):1920-34. PubMed ID: 15738310
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and characterization of the human homologue of the short PDE4A cAMP-specific phosphodiesterase RD1 (PDE4A1) by analysis of the human HSPDE4A gene locus located at chromosome 19p13.2.
    Sullivan M; Rena G; Begg F; Gordon L; Olsen AS; Houslay MD
    Biochem J; 1998 Aug; 333 ( Pt 3)(Pt 3):693-703. PubMed ID: 9677330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Membrane localization of cyclic nucleotide phosphodiesterase 3 (PDE3). Two N-terminal domains are required for the efficient targeting to, and association of, PDE3 with endoplasmic reticulum.
    Shakur Y; Takeda K; Kenan Y; Yu ZX; Rena G; Brandt D; Houslay MD; Degerman E; Ferrans VJ; Manganiello VC
    J Biol Chem; 2000 Dec; 275(49):38749-61. PubMed ID: 10952971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of recombinant human PDE4 isoforms: interaction with substrate and inhibitors.
    Saldou N; Obernolte R; Huber A; Baecker PA; Wilhelm R; Alvarez R; Li B; Xia L; Callan O; Su C; Jarnagin K; Shelton ER
    Cell Signal; 1998 Jun; 10(6):427-40. PubMed ID: 9720765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human phosphodiesterase 4A: characterization of full-length and truncated enzymes expressed in COS cells.
    Owens RJ; Catterall C; Batty D; Jappy J; Russell A; Smith B; O'Connell J; Perry MJ
    Biochem J; 1997 Aug; 326 ( Pt 1)(Pt 1):53-60. PubMed ID: 9337850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular cloning, genomic positioning, promoter identification, and characterization of the novel cyclic amp-specific phosphodiesterase PDE4A10.
    Rena G; Begg F; Ross A; MacKenzie C; McPhee I; Campbell L; Huston E; Sullivan M; Houslay MD
    Mol Pharmacol; 2001 May; 59(5):996-1011. PubMed ID: 11306681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification, characterization and regional distribution in brain of RPDE-6 (RNPDE4A5), a novel splice variant of the PDE4A cyclic AMP phosphodiesterase family.
    McPhee I; Pooley L; Lobban M; Bolger G; Houslay MD
    Biochem J; 1995 Sep; 310 ( Pt 3)(Pt 3):965-74. PubMed ID: 7575434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular cloning and subcellular distribution of the novel PDE4B4 cAMP-specific phosphodiesterase isoform.
    Shepherd M; McSorley T; Olsen AE; Johnston LA; Thomson NC; Baillie GS; Houslay MD; Bolger GB
    Biochem J; 2003 Mar; 370(Pt 2):429-38. PubMed ID: 12441002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occupancy of the catalytic site of the PDE4A4 cyclic AMP phosphodiesterase by rolipram triggers the dynamic redistribution of this specific isoform in living cells through a cyclic AMP independent process.
    Terry R; Cheung YF; Praestegaard M; Baillie GS; Huston E; Gall I; Adams DR; Houslay MD
    Cell Signal; 2003 Oct; 15(10):955-71. PubMed ID: 12873709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4.
    Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D
    Cell Signal; 2001 Apr; 13(4):287-97. PubMed ID: 11306246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TAPAS-1, a novel microdomain within the unique N-terminal region of the PDE4A1 cAMP-specific phosphodiesterase that allows rapid, Ca2+-triggered membrane association with selectivity for interaction with phosphatidic acid.
    Baillie GS; Huston E; Scotland G; Hodgkin M; Gall I; Peden AH; MacKenzie C; Houslay ES; Currie R; Pettitt TR; Walmsley AR; Wakelam MJ; Warwicker J; Houslay MD
    J Biol Chem; 2002 Aug; 277(31):28298-309. PubMed ID: 11994273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PDE4B5, a novel, super-short, brain-specific cAMP phosphodiesterase-4 variant whose isoform-specifying N-terminal region is identical to that of cAMP phosphodiesterase-4D6 (PDE4D6).
    Cheung YF; Kan Z; Garrett-Engele P; Gall I; Murdoch H; Baillie GS; Camargo LM; Johnson JM; Houslay MD; Castle JC
    J Pharmacol Exp Ther; 2007 Aug; 322(2):600-9. PubMed ID: 17519386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.